Reinnovated

Pharmaceuticals

We are pioneering the global chemical drug market worth KRW 1,000 trillion and securing a new engine for future growth.

Oncoquest™, manufactured using Aggregon® technology, is a personalized (autologous) therapeutic cancer vaccine that is prepared from the patient’s own tumor cells in combination with a focused delivery to the immune system of high dose powerful immune stimulator. Scientists from XEME developed this vaccine by taking advantage of the natural ability of the immune system to fight infections and malignant cells. Aggregon® vaccines are designed to stimulate the immune system to fight effectively against cancer progression and provide continuous protection against tumor relapse and spread (metastases).

Currently, XEME has two patent-pending applications that are being pursued by our intellectual property counsel (Banner and Witcoff Ltd., Chicago, IL). Importantly, XEME’s technology platform can be utilized to incorporate synthetic peptides, drugs, antibodies, adjuvants, silencing RNA or other small molecules into Aggregon® along with other immune-stimulatory cytokines and growth factors

XEME has also registered with the United States Patent and Trademark Office (“USPTO”) the trademark Aggregon® and claims common law trademark rights to Oncoquest™, each for use in its initial family of vaccine products.

For more information on pre-clinical and clinical studies supporting the use of XEME’s Aggregon® vaccine see: Experimental & Clinical Evidence

For more information on the unique advantages of XEME’s technology see: Why XEME’s Vaccine?

Gene Editing

Gene editing seeks to change DNA sequences within living cells. Gene editing has the potential to correct inherited or acquired genetic errors. To change a DNA sequence, two basic steps are required: first, to locate the DNA sequence of interest, and second, to correct that DNA sequence. We search for specific DNA sequences using proteins that naturally recognize DNA sequences. Several of these proteins can be reprogrammed to recognize a desired DNA sequence, thereby enabling the location of genes with mutations. Mutated DNA sequences can be corrected in many ways, including introducing a controlled DNA break, the most common form of gene editing. This controlled break, referred to as a DNA double-strand break, enables, in general, four types of changes.

Targeted mutagenesis

A small number of DNA bases are deleted or added at the site of the DNA double strand break.

Targeted deletion

In the DNA sequence, two DNA double-strand breaks are deleted.

Targeted insertion

A user-supplied DNA molecule is inserted at the site of a DNA double-strand break.

Precise modification

A user-supplied DNA molecule recombines with the sequence adjacent to the DNA double-stand break, resulting in the seamless correction of the DNA sequence.

Gene therapies

Gene therapies have the power to treat disease at the DNA level and address severe unmet medical needs.

At Precision BioSciences. we are focused on applying our proprietary GenomeGO genome-editing technology to cure genetic and infectious diseases where no adequate treatments exist. Gene editing technology has the incredible power to permanently cure devastating diseases; however, because gene edits are permanent, the risk of off-target or off-tissue gene edits can present a significant safety challenge.

Unlike some gene editing technologies that were designed primarily as research tools and subsequently engineered for therapeutic use, GenomeGO was designed with therapeutic safety, delivery and control in mind.

  • Highly specific GenomeGO platform

  • Potential to treat a wide range of diseases

  • Ease of delivery